Salutary effects of a novel oxidative stress modulator on adenine-induced chronic progressive tubulointerstitial nephropathy

American Journal of Translational Research

Volumn 4, Issue 3, 2012, Pages 257-268

  Nicholas, Susanne B ^a,b   Yuan, Jun ^c   Aminzadeh, Amin ^c   Norris, Keith C ^a,b   Crum, Albert ^d   Vaziri, Nosratola D ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Proimmune   (United States)

Author keywords

Glutathione disulfide; Glutathione precursor; Hematocrit; Inflammation; NF B p65; NF B; Oxidative stress modulator; p I B

Indexed keywords

ADENINE; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; CYSTEINE; CYSTINE; F1; FT 061452; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE H1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; RE 39734; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CHRONIC PROGRESSIVE TUBULOINTERSTITIAL NEPHROPATHY; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; DRUG EFFECT; EDEMA; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY CONCENTRATING CAPACITY; KIDNEY DYSFUNCTION; KIDNEY INJURY; MALE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; SWELLING; UREMIA;

EID: 84864998104     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N and Eknoyan G. Chronic kidney disease as a global public health problem: approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72: 247-259.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F and Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
3. Obrador GT, Mahdavi-Mazdeh M and Collins AJ. Establishing the Global Kidney Disease Prevention Network (KDPN): a position statement from the National Kidney Foundation. Am J Kidney Dis 2011; 57: 361-370.
4. Collins AJ, Gilbertson DT, Snyder JJ, Chen SC and Foley RN. Chronic kidney disease awareness, screening and prevention: rationale for the design of a public education program. Nephrology (Carlton) 2010; 15 Suppl 2: 37-42.
5. Ina K, Kitamura H, Tatsukawa S, Takayama T, Fujikura Y and Shimada T. Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy. Med Electron Microsc 2002; 35: 87-95.
6. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND and Nicholas SB. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009; 76: 32-43.
7. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J and Johnson RJ. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 2004; 286: F606-616.
8. Alsaad KO and Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol 2007; 60: 18-26.
9. Yokozawa T, Zheng PD, Oura H and Koizumi F. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44: 230-234.
10. Janaky R, Dohovics R, Hermann A, Oja SS and Saransaari P. Effects of metabotropic glutamate receptor agonists and antagonists on Daspartate release from mouse cerebral cortical and striatal slices. Neurochem Res 2001; 26: 1217-1224.
11. Jones DP. Redefining oxidative stress. Antioxid Redox Signal 2006; 8: 1865-1879.
12. Pompella A, Visvikis A, Paolicchi A, De Tata V and Casini AF. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 2003; 66: 1499-1503.
13. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J and Warnock DG. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336.
14. Adabag AS, Ishani A, Bloomfield HE, Ngo AK and Wilt TJ. Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials. Eur Heart J 2009; 30: 1910-1917.
15. Hilmi IA, Peng Z, Planinsic RM, Damian D, Dai F, Tyurina YY, Kagan VE and Kellum JA. Nacetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. Nephrol Dial Transplant 2010; 25: 2328-2333.
16. Rehman T, Fought J and Solomon R. Nacetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. Clin J Am Soc Nephrol 2008; 3: 1610-1614.
17. Shavit L, Korenfeld R, Lifschitz M, Butnaru A and Slotki I. Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. J Interv Cardiol 2009; 22: 556-563.
18. Kamgar M, Zaldivar F, Vaziri ND and Pahl MV. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. J Natl Med Assoc 2009; 101: 336-344.
19. Witschi A, Reddy S, Stofer B and Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol 1992; 43: 667-669.
20. Sinha-Hikim I, Shen R, Kovacheva E, Crum A, Vaziri ND and Norris KC. Inhibition of apoptotic signalling in spermine-treated vascular smooth muscle cells by a novel glutathione precursor. Cell Biol Int 2010; 34: 503-511.
21. Sinha-Hikim I, Sinha-Hikim AP, Shen R, Kim H, French SW, Vaziri ND, Crum A, Rajavashisth TB and Norris KC. A novel cystine based antioxidant attenuates oxidative stress and hepatic steatosis in diet-induced obese mice. Exp Mol Pathol 2011; 91: 419-428.
22. Crum A. Nutritional or therapeutic compositions to increases bodily glutathione levels. US. RE39734E. 2007.
23. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelerie F, Thomas D and Hay RT. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNAbinding and transcriptional activities of NFkappa B. Mol Cell Biol 1995; 15: 2689-2696.
24. Raij L, Azar S and Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984; 26: 137-143.
25. Alvarez V, Quiroz Y, Nava M, Pons H and Rodriguez-Iturbe B. Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 2002; 283: F1132-1141.
26. Quiroz Y, Pons H, Gordon KL, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ and Rodriguez-Iturbe B. Mycophenolate mofetil prevents saltsensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 2001; 281: F38-47.
27. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson RJ and Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002; 282: F191-201.
28. Barnes PJ and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
29. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 2004; 101: 4003-4008.
30. Souza JM, Peluffo G and Radi R. Protein tyrosine nitration--functional alteration or just a biomarker? Free Radic Biol Med 2008; 45: 357-366.
31. Quiroz Y, Ferrebuz A, Romero F, Vaziri ND and Rodriguez-Iturbe B. Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol 2008; 294: F336-344.
32. Quiroz Y, Ferrebuz A, Vaziri ND and Rodriguez-Iturbe B. Effect of chronic antioxidant therapy with superoxide dismutase-mimetic drug, tempol, on progression of renal disease in rats with renal mass reduction. Nephron Exp Nephrol 2009; 112: e31-42.
33. Ali BH, Al-Salam S, Al Husseni I, Kayed RR, Al-Masroori N, Al-Harthi T, Al Zaabi M and Nemmar A. Effects of Gum Arabic in rats with adenine-induced chronic renal failure. Exp Biol Med (Maywood) 2010; 235: 373-382.
34. Witschi A, Reddy S, Stofer B and Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol 1992; 43: 667-669.
35. Lawrence T, Gilroy DW, Colville-Nash PR and Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 2001; 7: 1291-1297.
36. Lawrence T and Fong C. The resolution of inflammation: anti-inflammatory roles for NFkappaB. Int J Biochem Cell Biol 2010; 42: 519-523.
37. Meyer S, Kohler NG and Joly A. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett 1997; 413: 354-358.
38. Auphan N, DiDonato JA, Rosette C, Helmberg A and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-290.
39. Guijarro C and Egido J. Transcription factorkappa B (NF-kappa B) and renal disease. Kidney Int 2001; 59: 415-424.
40. Wu G, Fang YZ, Yang S, Lupton JR and Turner ND. Glutathione metabolism and its implications for health. J Nutr 2004; 134: 489-492.
41. Zhu J, Li S, Marshall ZM and Whorton AR. A cystine-cysteine shuttle mediated by xCT facilitates cellular responses to S-nitrosoalbumin. Am J Physiol Cell Physiol 2008; 294: C1012-1020.
42. Li J, Bardag-Gorce F, Dedes J, French BA, Amidi F, Oliva J and French SW. Sadenosylmethionine prevents Mallory Denk body formation in drug-primed mice by inhibiting the epigenetic memory. Hepatology 2008; 47: 613-624.
43. Lin CC, Yin MC, Hsu CC and Lin MP. Effect of five cysteine-containing compounds on three lipogenic enzymes in Balb/cA mice consuming a high saturated fat diet. Lipids 2004; 39: 843-848.
44. Sinha-Hikim I, Shen R, Paul Lee WN, Crum A, Vaziri ND and Norris KC. Effects of a novel cystine-based glutathione precursor on oxidative stress in vascular smooth muscle cells. Am J Physiol Cell Physiol 2010; 299: C638-642.
45. Miyata T, Takizawa S and van Ypersele de Strihou C. Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: novel therapeutic targets. Am J Physiol Cell Physiol 2011; 300: C226-231.